(Bloomberg) -- Roche Holding AG said an experimental breast-cancer treatment will get an expedited review from US regulators ... based on research showing the medicine, called inavolisib, could ...

Swiss pharma company Roche ... FDA Priority Review status for a Perjeta (pertuzumab) regimen to be used before surgery (neoadjuvant treatment) in people with HER2-positive early stage breast cancer.

Roche has claimed a breakthrough ... HER2-negative breast cancer. That same month, Datroway was granted priority review by the FDA for EGFR-mutated NSCLC—which analysts have described as the ...

Get our list of 10 overlooked stocks—including one paying a 9% dividend—before Wall Street catches on. Roche Holdings AG ... (HER2)-positive early-stage breast cancer. After ten years, the ...

Foundation Medicine has developed the capability for high-throughput NGS analysis of genomic alterations covering more than 300 cancer ... for two Roche molecules, approved by the FDA and EMA ...

The FDA has completed its 30-day review of an application for Hepzato in combination with standard of care in liver-dominant metastatic breast cancer. Among patients with liver-dominant metastatic ...

Roche’s Perjeta (pertuzumab)-based regimen has demonstrated sustained survival benefits in patients with early-stage breast cancer, according to new results from a long-term study of the drug. The ...

FDA approval of Tepylute provides a ready-to-dilute thiotepa formulation for breast and ovarian cancer treatment, enhancing convenience and reducing preparation errors. The new formulation eliminates ...

A study involving an experimental cancer drug being developed by Roche ... HER2-positive breast cancer," said Kimberly Blackwell, the study's lead researcher and a professor of medicine at Duke ...